Table 2.
CMR findings in CFS patients and comparison with an age-matched control group of normal, female subjects
| Variables | CFS patients | Control group | Mean difference + 95 % CI | p value |
|---|---|---|---|---|
| LVEDD (mm) | 44 ± 3.7 | 49 ± 3.7 | 5 (2.68–7.66) | <0.05 |
| EDV (ml) | 129.8 ± 16.0 | 148.9 ± 19.0 | 19.1 (6.75–31.47) | <0.05 |
| EDV/BSA (ml/m2) | 77.5 ± 6.2 | 86.0 ± 9.3 | 8.4 (2.58–14.27) | <0.05 |
| LVESD (mm) | 29.7 ± 4.1 | 30.5 ± 3.2 | 0.8 (−1.48–3.18) | 0.47 |
| ESV (ml) | 54.7 ± 10.1 | 54.0 ± 9.2 | 0.7 (−6.99–5.71) | 0.84 |
| ESV/BSA (ml/m2) | 32.6 ± 4.0 | 30.9 ± 4.8 | 1.7 ± 1.6 (−4.92–1.48) | 0.29 |
| IVS (mm) | 7.9 ± 0.9 | 8.1 ± 1.1 | 0.3 (−0.44–0.97) | 0.46 |
| EDWM (g) | 60.6 ± 10.6 | 86.6 ± 11.7 | 26.0 (18.30–33.70) | <0.05 |
| EDWM/BSA (g/m2) | 39.8 ± 6.5 | 49.6 ± 7.1 | 9.9 (5.16–14.59) | <0.05 |
| SV (ml) | 75.0 ± 8.9 | 96.2 ± 11.7 | 21.2 (13.68–28.73) | <0.05 |
| SV/BSA (ml/m2) | 44.9 ± 4.5 | 54.9 ± 6.3 | 10.0 (6.07–14.03) | <0.05 |
| CO (l/min) | 4.9 ± 1.3 | 6.6 ± 1.2 | 1.7 (0.77–2.56) | <0.05 |
| LVEF (%) | 57.9 ± 4.3 | 63.7 ± 3.7 | 5.8 (3.19–8.41) | <0.05 |
| WMSI | 0.02 ± 0.04 | 0.00 ± 0.00 | 0.02 (−0.04–−0.01 | 0.054 |
| T2 weighted oedema (presence, n) | 0 | NA | NA | – |
| CE (presence, n) | 3 | 0 | – | – |
Data are expressed as mean ± standard deviation or frequencies and percentages
CI confidence interval, LVEDD left ventricular end-diastolic diameter, EDV end-diastolic volume, BSA body surface area, LVESD left ventricular end-systolic diameter, ESV end-systolic volume, IVS interventricular septum, EDWM end-diastolic wall mass, SV stroke volume, SVI stroke volume index, CO cardiac output, LVEF left ventricular ejection fraction, WMSI wall motion score index, CE contrast enhancement, NA not applicable